Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 3
1988 2
1990 2
1991 4
1992 1
1993 3
1994 4
1996 4
1997 5
1998 2
1999 1
2000 3
2001 4
2002 4
2003 5
2004 5
2005 4
2006 6
2007 7
2008 7
2009 5
2010 5
2011 3
2012 1
2013 4
2014 5
2015 3
2016 2
2017 2
2018 4
2019 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis.
Rajendran R, Rajendran V, Gupta L, Shirvanchi K, Schunin D, Karnati S, Giraldo-Velásquez M, Berghoff M. Rajendran R, et al. Int J Mol Sci. 2022 Oct 12;23(20):12183. doi: 10.3390/ijms232012183. Int J Mol Sci. 2022. PMID: 36293040 Free PMC article.
Recombinant beta interferons-1 (IFNbeta-1) are used as first line therapies in patients with relapsing multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the CNS. ...These data suggest that the beneficial effects in the chronic phase of …
Recombinant beta interferons-1 (IFNbeta-1) are used as first line therapies in patients with relapsing multiple sclerosis (MS) …
Betaseron.
Lin L. Lin L. Dev Biol Stand. 1998;96:97-104. Dev Biol Stand. 1998. PMID: 9890522
Betaseron, an analogue of human beta-interferon where serine was genetically engineered to substitute for cysteine at position 17, is produced in E. coli. ...These minor species were characterized with respect to their biological and biochemical properties, a …
Betaseron, an analogue of human beta-interferon where serine was genetically engineered to substitute for cysteine at p …
Glycoengineering of interferon-beta 1a improves its biophysical and pharmacokinetic properties.
Song K, Yoon IS, Kim NA, Kim DH, Lee J, Lee HJ, Lee S, Choi S, Choi MK, Kim HH, Jeong SH, Son WS, Kim DD, Shin YK. Song K, et al. PLoS One. 2014 May 23;9(5):e96967. doi: 10.1371/journal.pone.0096967. eCollection 2014. PLoS One. 2014. PMID: 24858932 Free PMC article.
The purpose of this study was to develop a biobetter version of recombinant human interferon-beta 1a (rhIFN-beta 1a) to improve its biophysical properties, such as aggregation, production and stability, and pharmacokinetic properties with …
The purpose of this study was to develop a biobetter version of recombinant human interferon-beta 1a (rhIFN-b …
Intact bioactivities and improved pharmacokinetic of the SL335-IFN-beta-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-beta.
Ji SI, Park JH, You HG, Chi HJ, Bang YW, Cha SH. Ji SI, et al. Immunol Lett. 2019 Mar;207:46-55. doi: 10.1016/j.imlet.2019.01.009. Epub 2019 Jan 23. Immunol Lett. 2019. PMID: 30684504
Recombinant human interferon beta (rIFN-beta) has long been used as a first-line treatment for multiple sclerosis (MS), and any attempt to develop a long-acting rIFN-beta is desirable since only one pegylated version of long-acting rIFN-beta …
Recombinant human interferon beta (rIFN-beta) has long been used as a first-line treatment for multiple sclerosi …
Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B, Cohen JA. Weinstock-Guttman B, et al. Drug Saf. 1996 Feb;14(2):121-30. doi: 10.2165/00002018-199614020-00006. Drug Saf. 1996. PMID: 8852526 Review.
Further, advances in trial methodology, including the availability of magnetic resonance imaging (MRI) as a surrogate outcome measure, have led to the identification of several new therapeutic options for relapsing-remitting (RR) MS. These therapies include corticosteroids, re …
Further, advances in trial methodology, including the availability of magnetic resonance imaging (MRI) as a surrogate outcome measure, have …
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
Coenen M, Hinze AV, Mengel M, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, Stingl J, Holdenrieder S, Müller M, Hartmann G, Coch C. Coenen M, et al. BMC Pharmacol Toxicol. 2015 Sep 22;16:25. doi: 10.1186/s40360-015-0025-x. BMC Pharmacol Toxicol. 2015. PMID: 26392348 Free PMC article. Clinical Trial.
Therefore, the ResI study was set up to analyze the human immune response to standard treatment with recombinant interferon-beta to establish biomarkers for safety and efficacy of the upcoming first-in-human trial investigating the RIG-I ligand. ...Three diff …
Therefore, the ResI study was set up to analyze the human immune response to standard treatment with recombinant interferon- …
The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.
Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, Shah S, Cooper J, Waris M, Yegutkin GG, Jalkanen J, Salmi M, Piippo I, Jalkanen M, Montgomery H, Jalkanen S. Bellingan G, et al. Lancet Respir Med. 2014 Feb;2(2):98-107. doi: 10.1016/S2213-2600(13)70259-5. Epub 2013 Dec 23. Lancet Respir Med. 2014. PMID: 24503265 Clinical Trial.
Production of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrier function. We tested whether interferon-beta-1a (IFN-beta-1a), which increases CD73 synthesis, can reduce vascular leakage and mortality i …
Production of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrier function. We tested whether i …
In vitro biological characterization of IFN-beta-1a major glycoforms.
Mastrangeli R, Rossi M, Mascia M, Palinsky W, Datola A, Terlizzese M, Bierau H. Mastrangeli R, et al. Glycobiology. 2015 Jan;25(1):21-9. doi: 10.1093/glycob/cwu082. Epub 2014 Aug 11. Glycobiology. 2015. PMID: 25117008
Recombinant human interferon beta-1a (IFN-beta-1a) is extensively used as the first-line treatment of relapsing forms of multiple sclerosis. ...The obtained fractions contained bi- and higher-antennarity glycans as described in the Europe …
Recombinant human interferon beta-1a (IFN-beta-1a) is extensively used as the first-line treatment …
Development of interferon-beta as a therapy for multiple sclerosis.
Markowitz C. Markowitz C. Expert Opin Emerg Drugs. 2004 Nov;9(2):363-74. doi: 10.1517/14728214.9.2.363. Expert Opin Emerg Drugs. 2004. PMID: 15571491 Review.
Two of the formulations consist of the naturally-occurring amino acid sequence of IFN-beta and are referred to as IFN-beta(1a). One is delivered intramuscularly (IM IFN-beta(1a)), and the second form of IFN-beta(1a) is delivered su …
Two of the formulations consist of the naturally-occurring amino acid sequence of IFN-beta and are referred to as IFN-beta( …
In vitro and computational studies on the effects of ARE deletion and targeted mutations on the expression of interferon beta-1a in HEK293T cells.
Norouzi R, Hojati Z, Dehbashi M. Norouzi R, et al. Appl Microbiol Biotechnol. 2018 Aug;102(16):7047-7059. doi: 10.1007/s00253-018-9162-7. Epub 2018 Jun 21. Appl Microbiol Biotechnol. 2018. PMID: 29931601
Interferon beta (IFNbeta) is transiently expressed in response to viral infections and widely used to treat relapsing-remitting multiple sclerosis (MS). ...In vitro experiments by quantitative real-time PCR, dot blot, SDS-PAGE, and Western blot assays showed an incr …
Interferon beta (IFNbeta) is transiently expressed in response to viral infections and widely used to treat relapsing-remittin …
104 results